Optima Capital’s Fennec Pharmaceuticals FENC Stock Holding History

Optima Capital’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-63	Closed	-$485	–	549
2025 Q4	$485	Buy	+63	New	+$517	﹤0.01%	1266

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Optima Capital's FENC Position: Q1 2026 in Review

Optima Capital sold out of Fennec Pharmaceuticals (FENC) in Q1 2026, closing a stake of 63 shares — an estimated $485 sold.

Optima Capital first reported a position in FENC in Q4 2025 and held it in 1 quarter. The position peaked at $485 in Q4 2025. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

Optima Capital reported no remaining Fennec Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Optima Capital sold 63 Fennec Pharmaceuticals shares in Q1 2026, an estimated $485.
Optima Capital first reported a position in Fennec Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Optima Capital's Fennec Pharmaceuticals position peaked at $485 in Q4 2025.
90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Optima Capital's 13F filing for Q1 2026, filed 5 May 2026.